Masumeh Rafati Javidan, MD
Hematology & Oncology · Brooklyn, NYNPI 1467699942
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $506, 2.6 times the $198 reported in 2019.
Across 98 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$194
- Daiichi Sankyo Inc.$147
- Eisai Inc.$120
- Bristol Myers Squibb$117
- E.r. Squibb & Sons, L.L.C.$112
- AbbVie$110
- plus $1K from 30 others
What the payments were for
- Food & beverage$1,91994%
- Education$1126%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 6 | $194 |
| Daiichi Sankyo Inc. | 7 | $147 |
| Eisai Inc. | 5 | $120 |
| Bristol Myers Squibb | 6 | $117 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| AbbVie | 5 | $110 |
| Novartis | 6 | $107 |
| Johnson & Johnson | 5 | $107 |
| Taiho Oncology, Inc. | 5 | $105 |
| Amgen | 5 | $88 |
| Gilead | 3 | $66 |
| Astellas Pharma US Inc | 4 | $60 |
| Seagen Inc. | 3 | $59 |
| Pfizer | 3 | $55 |
| GSK | 3 | $55 |
| Boehringer Ingelheim | 2 | $47 |
| Exelixis Inc. | 2 | $47 |
| Agios Pharmaceuticals, Inc. | 2 | $42 |
| Merck | 2 | $36 |
| Puma Biotechnology, Inc. | 2 | $31 |
| Beone Medicines USA, Inc. | 1 | $31 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Stryker | 1 | $22 |
| Sobi, Inc | 1 | $22 |
| Shield Therapeutics Inc | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Acceleron Pharma, Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Immunogen, Inc. | 1 | $13 |
How this compares
$2,031 in reported general payments places this provider in the 55th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 14 | $110 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Brooklyn
- Perry CookBrooklyn$803K
- Ilya BlokhBrooklyn$220K
- Yiwu HuangBrooklyn$220K
- Songchuan GuoBrooklyn$129K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.